

Special Issue

Role of Trace Elements in Chemoprevention and Cancer Therapy

Message from the Guest Editor

Trace elements are integral to the proper functioning of several important biochemical processes in a living body. A number of essential trace elements have been shown to play important roles in the etiology and prevention of chronic diseases, including cancer.

Supplementation by trace elements will likely overcome deficiency-induced complications but, to better achieve cancer reduction, emerging options of using trace elements containing natural and synthetic anticancer agents. These anticancer agents may be used in combination with existing chemotherapy to improve survival, or as an agent to sensitize drug-resistant tumors and reduce chemotherapy-induced toxicity.

Other emerging anticancer implications can include but are not limited to impact of trace elements on the tumor microenvironment, tumor hypoxia, tumor microbiota, and improvement of the immune system. This Special Issue invites original research (in vitro and in vivo), and/or reviews on mechanism-driven research developments for the use of trace elements and/or trace element-containing anticancer agents in chemoprevention and cancer therapy including but not limited to the specific areas mentioned above.

Guest Editor

Dr. Raghu Sinha

Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA, USA

Deadline for manuscript submissions

closed (15 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/77710

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).